Samsung Biologics operates as a fully integrated CDMO, providing end-to-end services from cell line development to commercial manufacturing. This segment encompasses upstream and downstream process development, analytical method development, formulation, aseptic filling, lyophilization, and quality control. The company leverages advanced technologies and methodologies to ensure efficient and high-quality biopharmaceutical production. Their R&D activities focus on optimizing manufacturing processes, enhancing cell line productivity, and developing innovative formulations. This segment serves a wide range of therapeutic areas, including oncology, immunology, and infectious diseases, with the goal of accelerating drug development and improving patient access to life-saving treatments. Samsung Biologics' strategic partnerships and collaborations further strengthen its market position and expand its service offerings.

Samsung Biologics is actively involved in the development and commercialization of biosimilar drugs through its subsidiary, Samsung Bioepis. This segment focuses on creating affordable alternatives to existing biologic medicines, thereby increasing patient access to critical therapies. R&D efforts are directed towards conducting rigorous clinical trials to demonstrate biosimilarity and ensure patient safety and efficacy. The company's biosimilar pipeline targets a range of therapeutic areas, including oncology and immunology. By leveraging its expertise in biopharmaceutical development and manufacturing, Samsung Biologics aims to provide cost-effective treatment options and contribute to the sustainability of healthcare systems. Strategic partnerships and collaborations play a crucial role in expanding the reach and impact of its biosimilar portfolio.